Verdugo-Sivianes Eva M, Carnero Amancio
Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville 41013, Spain.
CIBERONC, Instituto de Salud Carlos III, Madrid 28029, Spain.
Genes Dis. 2022 Feb 3;10(1):187-198. doi: 10.1016/j.gendis.2021.12.021. eCollection 2023 Jan.
SPINOPHILIN (SPN, PPP1R9B or NEURABIN-2) is a multifunctional protein that regulates protein-protein interactions in different cell signaling pathways. SPN is also one of the regulatory subunits of protein phosphatase 1 (PP1), implicated in the dephosphorylation of retinoblastoma protein (pRB) during cell cycle. The gene has been described as a tumor suppressor in different human tumor contexts, in which low levels of SPN are correlated with a higher grade and worse prognosis. In addition, mutations of the SPN protein have been reported in human tumors. Recently, an oncogenic mutation of SPN, A566V, was described, which affects both the SPN-PP1 interaction and the phosphatase activity of the holoenzyme, and promotes p53-dependent tumorigenesis by increasing the cancer stem cell (CSC) pool in breast tumors. Thus, the loss or mutation of SPN could be late events that promotes tumor progression by increasing the CSC pool and, eventually, the malignant behavior of the tumor.
亲嗜素(SPN,PPP1R9B或神经素-2)是一种多功能蛋白,可调节不同细胞信号通路中的蛋白质-蛋白质相互作用。SPN也是蛋白磷酸酶1(PP1)的调节亚基之一,参与细胞周期中视网膜母细胞瘤蛋白(pRB)的去磷酸化过程。该基因在不同的人类肿瘤背景中被描述为一种肿瘤抑制因子,其中SPN水平较低与肿瘤分级较高和预后较差相关。此外,人类肿瘤中已报道了SPN蛋白的突变。最近,描述了一种SPN的致癌突变A566V,它既影响SPN-PP1相互作用又影响全酶的磷酸酶活性,并通过增加乳腺肿瘤中的癌症干细胞(CSC)池来促进p53依赖性肿瘤发生。因此,SPN的缺失或突变可能是通过增加CSC池并最终促进肿瘤恶性行为来推动肿瘤进展的晚期事件。